The MHRA has concluded its four year investigation into Glaxosmithkline and its antidepressant drug Seroxat. The investigation focused on whether GSK had failed to inform the MHRA of information it had on the safety of Seroxat in under 18’s in a timely manner. The investigation was undertaken with a view to a potential criminal prosecution for breach of drug safety legislation.
Popularity: unranked [?]
Related posts:
- GSK Statement On MHRA Investigation
- European Medicines Agency Concludes New Advice To Doctors And Patientsfor Champix Needed
- European Medicines Agency Concludes New Advice To Doctors And Patientsfor Champix Needed
- Mind: Public Must Be Able To Have Trust In Medicines, Says Mental Health Charity ‘Mind’, UK
- NY Health Department Launches MySpace Campaign To Help Young New Yorkers Cope
Comments
No Responses to “GSK Investigation Concludes”